Evidence map›Paper›PMID 22453138›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012

Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia.

Philip L Johnson, Brian C Samuels, Stephanie D Fitz, Stafford L Lightman, Christopher A Lowry, Anantha Shekhar

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02593682 (The Role of Orexin in Human Panic Disorder), which is not on this map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02593682 phase4completednot on this mapstarted 2016, after this paper: background citation

The Role of Orexin in Human Panic Disorder

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2020Enrolled3ConditionsPanic DisorderArmssuvorexant, placebo
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 103 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Sex differences in responses to panicogen COFrontiers in cellular neuroscience · 2026
    Article
  6. COAddiction biology · 2026
    Article
  7. Associations of COPhysiology & behavior · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. COPhysiology & behavior · 2023
    Article
  13. Review
  14. Article
  15. COBMC psychiatry · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Philip L JohnsonInstitute of Psychiatric Research in the Department of Psychiatry, Indianapolis, IN, USA. philjohn@iupui.edu
Brian C Samuels
Stephanie D Fitz
Stafford L Lightman
Christopher A Lowry
Anantha Shekhar
Cleveland Research (United States) · USIndiana University – Purdue University Indianapolis · USIndiana University School of MedicineUniversity of Bristol · GBUniversity of Colorado Boulder · US

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
NEUROBIOLOGY OF PANIC AND ANXIETY DISORDERSR01MH052619 · NIMH · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SHEKHAR, ANANTHA · 1996 to 2016
$5.0M
Indiana Clinical and Translational Science Institute-K12 ProgramKL2RR025760 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$2.2M
NCATS NIH HHS UL1 TR001108NCRR NIH HHS KL2 RR025760NCRR NIH HHS UL1 RR025761NIMH NIH HHS L30 MH081659NIMH NIH HHS R01 MH052619NIMH NIH HHS R01 MH52619
6 · The paper itself

Abstract

Acute hypercapnia (elevated arterial CO(2)/H(+)) is a suffocation signal that is life threatening and rapidly mobilizes adaptive changes in breathing and behavioral arousal in order to restore acid-base homeostasis. Severe hypercapnia, seen in respiratory disorders (eg, asthma or bronchitis, chronic obstructive pulmonary disease (COPD)), also results in high anxiety and autonomic activation. Recent evidence has demonstrated that wake-promoting hypothalamic orexin (ORX: also known as hypocretin) neurons are highly sensitive to local changes in CO(2)/H(+), and mice lacking prepro-ORX have blunted respiratory responses to hypercapnia. Furthermore, in a recent clinical study, ORX-A, which crosses blood-brain barrier easily, was dramatically increased in the plasma of patients with COPD and hypercapnic respiratory failure. This is consistent with a rodent model of COPD where chronic exposure to cigarette smoke led to a threefold increase in hypothalamic ORX-A expression. In the present study, we determined the role of ORX in the anxiety-like behavior and cardiorespiratory responses to acute exposure to a threshold panic challenge (ie, 20% CO(2)/normoxic gas). Exposing conscious rats to such hypercapnic, but not atmospheric air, resulted in respiratory, pressor, and bradycardic responses, as well as anxiety-like behavior and increased cellular c-Fos responses in ORX neurons. Systemically, pre-treating rats with a centrally active ORX1 receptor antagonist (30 mg/kg SB334867) attenuated hypercapnic gas-induced pressor and anxiety responses, without altering the robust bradycardia response, and only attenuated breathing responses at offset of the CO(2) challenge. Our results show that the ORX system has an important role in anxiety and sympathetic mobilization during hypercapnia. Furthermore, ORX1 receptor antagonists may be a therapeutic option rapidly treating increased anxiety and sympathetic drive seen during panic attacks and in hypercapnic states such as COPD.

Indexed as

AnimalsAnxietyBenzoxazolesBradycardiaDisease Models, AnimalHypercapniaHypertensionIntracellular Signaling Peptides and ProteinsMaleNaphthyridinesNeuronsNeuropeptidesOrexin ReceptorsOrexinsRatsRats, Sprague-Dawley1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl ureaBenzoxazolesIntracellular Signaling Peptides and ProteinsNaphthyridinesNeuropeptidesOrexin ReceptorsOrexinsReceptors, G-Protein-CoupledReceptors, NeuropeptideUrea

Identifiers

PMID22453138
PMCPMC3376323
OpenAlexW1983465167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.